Bal Pharma Ltd

Bal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bal Pharma Ltd

₹ 71.8 1.06%
14 Jan - close price
balpharma.com BSE: 524824 NSE: BALPHARMA
About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Key Points

Business Overview:[1]
BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.

Website BSE NSE
  • Market Cap ₹ 114 Cr.
  • Current Price ₹ 71.8
  • High / Low ₹ 129 / 67.2
  • Stock P/E 15.4
  • Book Value ₹ 62.8
  • Dividend Yield 1.67 %
  • ROCE 9.69 %
  • ROE 8.14 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 1.14 times its book value
  • Company has been maintaining a healthy dividend payout of 24.9%
  • Company's working capital requirements have reduced from 40.4 days to 28.7 days

Cons

  • Company has low interest coverage ratio.
  • Tax rate seems low
  • Company has a low return on equity of 7.65% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
75.05 76.56 81.97 70.17 92.30 81.49 94.58 73.13 74.70 72.89 81.78 65.64 73.75
69.04 70.25 73.70 63.33 84.64 73.67 85.40 66.57 67.23 64.96 73.95 59.49 67.97
Operating Profit 6.01 6.31 8.27 6.84 7.66 7.82 9.18 6.56 7.47 7.93 7.83 6.15 5.78
OPM % 8.01% 8.24% 10.09% 9.75% 8.30% 9.60% 9.71% 8.97% 10.00% 10.88% 9.57% 9.37% 7.84%
0.38 0.77 0.44 0.45 0.41 0.26 1.85 0.29 0.35 0.51 0.99 0.74 1.13
Interest 2.83 3.12 3.84 3.64 3.82 3.86 3.34 3.71 4.18 5.02 3.94 4.05 3.86
Depreciation 1.96 2.03 1.66 2.12 2.02 2.55 2.14 2.43 2.12 2.68 2.07 2.52 2.27
Profit before tax 1.60 1.93 3.21 1.53 2.23 1.67 5.55 0.71 1.52 0.74 2.81 0.32 0.78
Tax % 29.38% 23.83% 33.64% 22.22% 28.25% 25.15% 3.78% 50.70% 21.05% 5.41% -99.29% 0.00% 0.00%
1.13 1.47 2.12 1.20 1.60 1.26 5.34 0.36 1.20 0.69 5.61 0.32 0.78
EPS in Rs 0.73 0.94 1.35 0.76 1.02 0.80 3.38 0.23 0.75 0.43 3.52 0.20 0.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
179 187 198 226 210 223 171 249 280 303 339 302 294
161 170 181 206 187 203 164 223 257 277 307 272 266
Operating Profit 18 18 17 20 23 20 7 27 23 26 32 30 28
OPM % 10% 9% 9% 9% 11% 9% 4% 11% 8% 9% 9% 10% 9%
1 1 2 3 2 3 4 3 6 2 2 2 3
Interest 7 7 6 8 9 13 13 12 11 13 15 17 17
Depreciation 5 7 7 6 7 6 7 7 7 7 10 10 10
Profit before tax 7 5 5 9 8 4 -9 10 12 9 9 6 5
Tax % 23% 23% 46% 38% 30% -53% -2% 7% 29% 28% 17% -36%
5 4 3 5 6 7 -9 9 9 6 8 8 7
EPS in Rs 4.56 3.12 2.18 3.75 4.19 4.77 -6.28 6.14 5.79 3.91 4.89 4.90 4.64
Dividend Payout % 22% 32% 46% 27% 24% 21% 0% 16% 17% 26% 25% 24%
Compounded Sales Growth
10 Years: 5%
5 Years: 12%
3 Years: 3%
TTM: -9%
Compounded Profit Growth
10 Years: 7%
5 Years: 24%
3 Years: 0%
TTM: -9%
Stock Price CAGR
10 Years: -4%
5 Years: 5%
3 Years: -6%
1 Year: -38%
Return on Equity
10 Years: 7%
5 Years: 9%
3 Years: 8%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 11 13 13 14 14 14 14 15 15 16 16 16 16
Reserves 39 43 44 52 58 63 52 64 72 80 77 83 84
51 49 70 74 91 104 99 104 98 125 134 145 149
54 59 67 78 88 76 74 78 104 126 108 107 116
Total Liabilities 155 164 193 219 251 257 239 262 290 348 334 351 365
55 52 56 60 58 57 56 53 53 63 79 87 92
CWIP 0 1 4 2 0 0 0 0 1 0 0 3 3
Investments 0 1 1 0 7 7 7 8 8 8 9 5 3
99 110 132 157 185 193 176 200 227 276 245 256 267
Total Assets 155 164 193 219 251 257 239 262 290 348 334 351 365

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
13 14 1 6 13 12 22 10 31 5 29 20
-7 -6 -14 -8 -16 -12 -3 -7 -13 -22 -19 -15
-8 -7 12 2 4 0 -20 -3 -17 17 -7 -8
Net Cash Flow -2 2 -0 0 1 -0 -2 0 -0 0 3 -2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 93 88 105 99 111 107 110 102 101 114 110 114
Inventory Days 122 132 145 171 240 217 291 146 162 210 167 238
Days Payable 129 142 163 168 183 148 170 118 158 195 148 189
Cash Conversion Cycle 86 78 87 101 168 176 232 130 105 129 129 163
Working Capital Days 11 15 17 38 77 68 55 62 61 61 32 29
ROCE % 14% 11% 10% 13% 12% 10% 2% 13% 12% 10% 11% 10%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
51.61% 51.61% 51.61% 51.24% 51.24% 51.24% 50.87% 50.87% 50.87% 50.87% 50.87% 50.87%
0.17% 0.17% 0.14% 0.13% 0.13% 0.13% 0.13% 0.14% 0.14% 0.15% 0.23% 0.14%
48.23% 48.23% 48.25% 48.64% 48.64% 48.63% 49.01% 49.00% 49.01% 48.99% 48.91% 49.01%
No. of Shareholders 16,02915,86915,52915,06014,77215,01416,00715,66715,72315,82615,77415,520

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

  • Feb 2023
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT